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Protective effects of breastfeeding on respiratory symptoms
in infants with 17q21 asthma risk variants
To the Editor,
Genetic polymorphisms at the 17q21 locus have been associated
with the subsequent onset of childhood asthma and appear to
strengthen the association between childhood asthma and early epi-
sodes of wheezing.1,2 A recent study of Loss et al2 showed that
17q21 alleles modified the effect of exposure to older siblings and
animal shed on episodes of wheeze in infancy. As environmental fac-
tors seem to play a role with respect to the effect modification by
the 17q21 polymorphism, our aim was to assess whether the associ-
ation between asthma‐associated 17q21 variants, and lower respira-
tory symptoms during the 1st year of life, may be modified by
breastfeeding. In addition, we investigated whether the described
interactions with other environmental exposures, such as older sib-
lings2 and tobacco exposure,3,4 were reproducible.
We tested our hypothesis within the prospective Basel‐Bern
Infant Lung Development (BILD) birth cohort of healthy unselected
infants (n = 368) living in urban environments.5 Parental written
informed consent was obtained, and the study was approved by the
Ethics Committees of Basel and Bern. Respiratory symptoms, such
as occurrence of cough, wheeze, or difficulty breathing during the
night and day—and their severity—were assessed by weekly tele-
phone interviews using a standardized symptom score (each on a
scale of 0‐4, with 0 indicating no symptoms and ≥3 severe symp-
toms).5 As a primary outcome, the respiratory symptom score was cal-
culated as a sum total of daytime and nighttime symptom scores (on
a scale of 0‐8).5 The secondary outcome was episodes of wheeze in
the 1st year of life that were defined as a whistling sound in the
chest audible to the parents, or doctor‐diagnosed wheeze. Wheeze
episodes have been recorded since 2004 on a weekly basis (based
on a “yes or no” question); therefore, we restricted our sample to
those infants with complete information on wheeze (n = 252).
Genomewide genotyping was performed using Illumina Huma-
nOmniExpress Bead Chips (Illumina Inc., San Diego, CA, USA). Five
major tagging SNPs at the locus 17q21: rs7216389, rs4795405,
rs8079416, rs8065126, and rs3902025 were included in the analy-
sis. These variants were selected as representative of the five high-
est asthma‐associated tagging bins based on unpublished 17q21 fine
mapping data (1446 children, 763 asthmatics, from the German
MAGIC and ISAAC II studies), presented at the 11th Meeting of the
European Human Genetics Societies. For the purposes of our study,
either the major tagging SNP from the respective bin (rs3902025) or
a proxy in high linkage disequilibrium was analyzed.
Generalized additive mixed model with quasi‐Poisson and bino-
mial distribution for count and binary outcomes was used to investi-
gate weekly measured respiratory symptom scores and any
breastfeeding (“yes or no” for each week under observation). We
applied autoregressive AR(1) modeling to account for interchild vari-
ation. Each SNP was coded as 0/1/2 for the number of risk alleles
and analyzed separately under the additive model. The interaction
was tested by adding to the adjusted model the multiplicative inter-
action term between breastfeeding and SNP.
Next, we attempted a replication of top SNPs within the Protec-
tion against Allergy Study in Rural Environments (PASTURE) birth
cohort study (n = 799) that was conducted in rural areas. Informa-
tion on respiratory symptoms (defined as the presence of wheeze or
cough) and any breastfeeding was collected from weekly and 4‐
weekly diaries. We used a stringent Bonferroni P‐value correction
threshold of 0.01 (0.05/5) and 0.025 (0.05/2) for discovery and repli-
cation analysis, respectively. Further information on demographic
(eTable 1) and genotype characteristics, methods, and meta‐analyses
of both cohorts is provided in the Supporting Information.
The 17q21 SNPs were not associated with respiratory symptom
score during the 1st year of life. When we stratified infants by
breastfeeding status, we found that, during those weeks when
infants were breastfed, the carriers of asthma risk alleles of the#Members of the BILD and PASTURE study groups are listed in the Appendix.
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most strongly associated SNPs (rs7216389‐T and rs4795405‐C,
Table 1) were more responsive to the protective effect of breast-
feeding on respiratory symptoms. In contrast, during those weeks
when infants were not breastfed, the same genotype showed a
trend toward an increased risk of respiratory symptoms, resulting
in a significant interaction effect for both SNPs (P for interaction
0.0006 and 0.0041, respectively, Table 1). Although the direction
of the association in the entire wheeze subset of infants, and
across strata by breastfeeding, was the same as in the main analy-
sis, no significant interaction was observed between the 17q21
locus and breastfeeding in relation to wheeze that may be
explained by limited power and conservative correction for multiple
comparisons.
In the PASTURE cohort, the protective effect of breastfeeding
on wheeze was present only in carriers of asthma risk alleles of
rs8076131 (the closest proxy of rs4795405, r2 = 0.92; r2‐value is
based on a study by Toncheva et al6) (Figure 1). Similar effects
were observed in carriers of risk alleles of rs4795405 in relation to
wheeze in the BILD cohort. However, we found no evidence for
an interaction. The meta‐analysis of interaction effects in the BILD
and PASTURE data yields a borderline significant effect for
rs4795405 (P = 0.028, eFigure 1). Factors that may weaken the
breastfeeding interaction in the PASTURE cohort were population‐
specific genetic and environmental factors, such as high farm expo-
sure and an interaction of breastfeeding status with farming expo-
sure in relation to respiratory symptoms (data not shown). We
hypothesize that the influence of the 17q21 locus on respiratory
symptoms may be modified by multiple environmental factors, and
their relative small size impact may depend on the environmental
context.
In accordance with Loss et al,2 we were able to replicate the
interaction between the 17q21 locus and the presence of older sib-
lings. Consistent with other studies,2,3 we did not find interaction
with maternal smoking during pregnancy (eTable 2).
There are several interpretations we can consider on the interac-
tion between 17q21 SNPs and breastfeeding in relation to
TABLE 1 Associationa of 17q21 genotype (additive effect for risk allele) with respiratory symptoms and wheeze by breastfeeding
SNP Risk allele
Total
Stratum by exposure
P‐value interactionb
Weeks with breastfeeding Weeks without breastfeeding
RR (95% CI)/OR (95% CI) RR (95% CI)/OR (95% CI) RR (95% CI)/OR (95% CI)
Discovery: BILD (n = 368 and 252 for respiratory symptoms and wheeze, respectively)
Respiratory symptomsc No. of weeks = 19 252 No. of weeks = 12 511 No. of weeks = 6741
rs7216389 T 0.98 (0.90‐1.08) 0.82 (0.72-0.93) 1.09 (0.96‐1.24) 0.0006
rs4795405 C 1.03 (0.94‐1.12) 0.85 (0.74‐0.97) 1.10 (0.97‐1.24) 0.0041
rs8079416 C 1.07 (0.98‐1.16) 0.97 (0.85‐1.11) 1.07 (0.94‐1.21) 0.217
rs8065126 C 1.10 (1.01‐1.21) 1.01 (0.88‐1.15) 1.12 (0.98‐1.26) 0.125
rs3902025 T 1.10 (1.00‐1.10) 1.01 (0.88‐1.16) 1.12 (0.98‐1.27) 0.204
Wheezed No. of weeks = 13 101 No. of weeks = 8564 No. of weeks = 4537
rs7216389 T 0.91 (0.67‐1.22) 0.65 (0.39‐1.09) 1.12 (0.76‐1.67) 0.052
rs4795405 C 0.90 (0.67‐1.22) 0.59 (0.34‐1.02) 1.17 (0.79‐1.73) 0.020
rs8079416 C 1.15 (0.85‐1.57) 1.05 (0.62‐1.76) 1.25 (0.84‐1.88) 0.718
rs8065126 C 1.08 (0.77‐1.51) 0.69 (0.40‐1.17) 1.46 (0.93‐2.28) 0.037
rs3902025 T 1.16 (0.84‐1.61) 0.89 (0.50‐1.57) 1.37 (090‐2.08) 0.253
Replication: PASTURE (n = 799)
Respiratory symptomsd No. of weeks = 31 691 No. of weeks = 14 734 No. of weeks = 16 957
rs7216389 T 1.10 (1.02‐1.19) 1.11 (0.98‐1.27) 1.11 (1.00‐1.22) 0.689
rs8076131 A 1.06 (0.98‐1.14) 0.99 (0.88‐1.33) 1.11 (1.01‐1.22) 0.370
Wheezed
rs7216389 T 1.10 (0.95‐1.26) 1.03 (0.81‐1.31) 1.15 (0.97‐1.36) 0.799
rs8076131 A 1.12 (0.97‐1.29) 0.95 (0.74‐1.20) 1.24 (1.04-1.46) 0.174
aAdjusted for sex, week of age, the presence of older siblings, birthweight, gestational age, mode of delivery, child care, maternal education, maternal/
parental atopy, maternal smoking in pregnancy, week of study, and study centers. In the replication analysis, the association was additionally adjusted
for farm exposure.
bInteraction was tested by adding the product between breastfeeding and corresponding SNP in the adjusted model.
cPer‐allele RR and 95% CI derived from generalized additive mixed model with quasi‐Poisson distribution.
dPer‐allele OR and 95% CI derived from generalized additive mixed model with binomial distribution.
Significant associations after Bonferroni correction are in boldface.
BILD, Basel‐Bern Infant Lung Development birth cohort; PASTURE, Protection against Allergy Study in Rural Environments birth cohort; OR, odds ratio;
RR, risk ratio; CI, confidence interval.
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respiratory symptoms. First, breastmilk is rich in immune compo-
nents inhibiting virus replication, regulating mucosal immunity,7 and
shifting the gut microbiota toward species which strengthen the
immune response.8 Second, the 17q21 locus may increase suscepti-
bility to viral infection.1 Third, DNA methylation in CpG cites of
rs7216389 and rs4795405 was associated with mRNA expression of
orosomucoid‐like 3 (ORMDL3) gene.9 This would make carriers of
the asthma risk genotype potentially more responsive to the protec-
tive effect of breastfeeding. Finally, epigenetic phenomena are
known to be related to 17q21.10
In conclusion, our findings demonstrated evidence suggestive of
interaction between 17q21 variants and breastfeeding in relation to
respiratory symptoms in the 1st year of life. Infants with the asthma
risk allele might particularly profit from the protective effect of
breastfeeding on early‐life respiratory infection, which is an impor-
tant target for secondary asthma prevention. As multiple exposures
seem to affect 17q21 in a complex manner, observed gene‐environ-
ment interactions may be specific for a given environment (eg, rural
versus urban context).
ACKNOWLEDGMENTS
We thank our study participants and their families for their participation.
We thank Karine Hugentobler (University of Basel Children's Hospital)
for proofreading the manuscript. Furthermore, we thank the entire BILD
cohort team (University of Basel Children's Hospital, Switzerland; Divi-
sion of Respiratory Medicine, Department of Pediatrics, Inselspital, Bern
University Hospital, University of Bern, Switzerland).
CONFLICTS OF INTEREST
Dr. von Mutius reports holding grants from the European Commis-
sion, the European Research Council, and the German Research
Foundation, during the conduct of the study. Dr. von Mutius has also
received personal fees from the following organizations for her con-
tribution outside the context of the submitted work: the American
Academy of Allergy, Asthma & Immunology, the Ökosoziales Forum
Oberösterreich, Mundipharma, HAL Allergie GmbH, from DOC Con-
gress SRL, American Thoracic Society, University of Tampere; GBS
RE HEFCE, Novartis Pharma, OM Pharma SA, AbbVie Deutschland
GmbH & Co. KG, medUpdate GmbH, and System Analytic Ltd.
Dr. Latzin reports personal fees from OM Pharma SA, Roche,
Vertex and Gilead, all outside of the submitted work.
Dr. Frey reports a personal fee from a GSK scientific board
meeting 2016, outside of the submitted work.
Dr. Pekkanen reports holding grants from the European Commis-
sion and Academy of Finland during the conduct of the study.
Dr. Lauener reports holding grants from the Kühne Foundation/
Christine Kühne‐Center for Allergy Research and Education, the
European Union and the Swiss National Research Foundation during
the conduct of the study. Dr. Lauener has received fees and/or
served on advisory boards from Menarini, Meda, Nestlé, AstraZe-
neca, the Pfizer Research Prize Foundation, Vifor and the Swiss
Government, all outside of the submitted work.
Dr. Kabesch reports holding grants from the European Union,
German Ministry of Education and Research, German Research
Foundation during the conduct of the study. Dr. Kabesch reports a
F IGURE 1 Associations of
breastfeeding with respiratory symptoms
and wheeze in the BILD discovery cohort
and in PASTURE replication cohort
according to rs7216389 and rs4795405
(the proxy is rs8076131): (A) respiratory
symptoms and rs7216389; (B) wheeze and
rs7216389; (C) respiratory symptoms and
rs4795405 (the proxy is rs8076131); (D)
wheeze and rs4795405 (the proxy is
rs8076131). Associations (*Bonferroni‐
significance) were adjusted for sex, week
of age, the presence of older siblings,
birthweight, gestational age, mode of
delivery, child care, maternal education,
maternal/parental atopy, maternal smoking
in pregnancy, week of study, and study
centers. In the replication cohort, the
association was additionally adjusted for
farm exposure. Results were expressed as
a risk ratio (RR) for the association
between respiratory symptom score in the
BILD cohort and as an odds ratio (OR) for
other associations. All estimates are given
with 95% confidence interval (95% CI)
2390 | LETTER TO THE EDITOR
personal fees from Bionorica, ERS, EAACI, ATS, Novartis, Glaxo,
Nutricia, and Hipp, all outside of the submitted work.
AUTHOR CONTRIBUTIONS
Drs Gorlanova and Illi had full access to all the data in the study and
take responsibility for the integrity of the data and the accuracy of
the data analysis. Study concept and design: Urs Frey, Olga Gor-
lanova, Sabina Illi, Michael Kabesch, Philipp Latzin, Erika von Mutius,
and Antoaneta A. Toncheva. Acquisition, analysis, or interpretation
of data: All authors. Drafting of the manuscript: Olga Gorlanova, Urs
Frey. Critical revision of the manuscript for important intellectual
content: All authors. Statistical analysis: Olga Gorlanova, Sabina Illi.
Obtained funding: Urs Frey. Study supervision: Urs Frey, Olga Gor-
lanova.
FUNDING INFORMATION
This work was supported by the Swiss National Science Foundation
(Schweizerischer Nationalfonds zur Förderung der Wis-
senschaftlichen Forschung) (grant nos. 320030_163311, 32003B-
144068, and 32003B_162820).
O. Gorlanova1
S. Illi2,3,4
A. A. Toncheva5
J. Usemann1,6
P. Latzin6
M. Kabesch5
J.-C. Dalphin7
R. Lauener8,9
J. R. Pekkanen10,11
E. Von Mutius2,3,4
J. Riedler12
C. E. Kuehni13
M. Röösli14
U. Frey1
on behalf of the BILD and PASTURE study groups#
1University Children's Hospital (UKBB), University of Basel, Basel,
Switzerland
2Dr von Hauner Children's Hospital, Ludwig Maximilian University,
Munich, Germany
3Comprehensive Pneumology Center Munich (CPC-M), Munich, Germany
4Member of the German Center for Lung Research, Munich, Germany
5Department of Pediatric Pneumology and Allergy, University Children's
Hospital Regensburg (KUNO), Regensburg, Germany
6Division of Respiratory Medicine, Department of Paediatrics, Inselspital,
Bern University Hospital, University of Bern, Bern, Switzerland
7Department of Respiratory Disease, UMR/CNRS 6249 Chrono-
environment, University Hospital, University of Besançon, Besançon,
France
8Children's Hospital of Eastern Switzerland, St. Gallen, Switzerland
9Christine Kühne Center for Allergy Research and Education (CK-CARE),
Davos, Switzerland
10National Institute for Health and Welfare, Kuopio, Finland
11Department of Public Health, University of Helsinki, Helsinki, Finland
12Children's Hospital Schwarzach, Teaching Hospital Paracelsus Private
Medical University Salzburg, Salzburg, Austria
13Institute for Social and Preventive Medicine, University of Bern, Bern,
Switzerland
14Swiss Tropical and Public Health Institute Basel, Basel, Switzerland
Correspondence: Olga Gorlanova, MD, University Children's Hospital
(UKBB), Spitalstrasse 33, 4056 Basel, Switzerland
(olga.gorlanova@ukbb.ch).
REFERENCES
1. Çalışkan M, Bochkov YA, Kreiner-Møller E, et al. Rhinovirus wheez-
ing illness and genetic risk of childhood‐onset asthma. N Engl J Med.
2013;368:1398‐1407.
2. Loss GJ, Depner M, Hose AJ, et al. The early development of
wheeze. Environmental determinants and genetic susceptibility at
17q21. Am J Respir Crit Care Med. 2016;193:889‐897.
3. Brauner EV, Loft S, Raaschou-Nielsen O, Vogel U, Andersen PS, Soren-
sen M. Effects of a 17q21 chromosome gene variant, tobacco smoke
and furred pets on infant wheeze. Genes Immun. 2012;13:94‐97.
4. Bouzigon E, Corda E, Aschard H, et al. Effect of 17q21 variants and
smoking exposure in early‐onset asthma. N Engl J Med. 2008;359:
1985‐1994.
5. Gorlanova O, Thalmann S, Proietti E, et al. Effects of breastfeeding on
respiratory symptoms in infancy. J Pediatr. 2016;174:111‐117.
6. Toncheva A, Potaczek D, Schedel M, et al. Childhood asthma is asso-
ciated with mutations and gene expression differences of ORMDL
genes that can interact. Allergy. 2015;70:1288‐1299.
7. Oddy WH. A review of the effects of breastfeeding on respiratory
infections, atopy, and childhood asthma. J Asthma. 2004;41:605‐621.
8. Fernández L, Langa S, Martín V, et al. The human milk microbiota:
origin and potential roles in health and disease. Pharmacol Res. 2013;
69:1‐10.
9. Acevedo N, Reinius LE, Greco D, et al. Risk of childhood asthma is
associated with CpG‐site polymorphisms, regional DNA methylation
and mRNA levels at the GSDMB/ORMDL3 locus. Hum Mol Genet.
2015;24:875‐890.
10. Hartwig FP, de Mola CL, Davies NM, Victora CG, Relton CL. Breast-
feeding effects on DNA methylation in the offspring: a systematic
literature review. PLoS One. 2017;12:e0173070.
SUPPORTING INFORMATION
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
APPENDIX
GROUP INFORMATION
The Basel‐Bern Infant Lung Development (BILD) cohort was part of
the collaboration responsible for this work. Its current members are
LETTER TO THE EDITOR | 2391
as follows (in alphabetical order): Pinelopi Anagnostopoulou, MD
(Bern University Hospital, Bern); Urs Frey, PhD (University of Basel
Children's Hospital, Basel); Oliver Fuchs, PhD (Bern University Hospi-
tal, Bern); Olga Gorlanova, MD (University of Basel Children's Hospi-
tal, Basel); Insa Korten, PhD (Bern University Hospital, Bern); Philipp
Latzin, PhD (Bern University Hospital); Loretta Müller, PhD (Univer-
sity of Basel Children's Hospital, Basel); Elena Proietti, PhD (Univer-
sity of Zurich Children's Hospital, Zurich); Anne Schmidt, PhD
((University of Basel Children's Hospital, Basel); Jakob Usemann, PhD
(University of Basel Children's Hospital, Basel). The Protection
against Allergy Study in Rural Environments (PASTURE) cohort, cur-
rent study group (in alphabetical order by study center):
Finland: Anne Hyvärinen, PhD (National Institute for Health and
Welfare, Kuopio); Anne Karvonen, PhD, (National Institute for Health
and Welfare, Kuopio); Pirkka Kirjavainen, PhD, (National Institute for
Health and Welfare, Kuopio); Sami Remes, MSc, (National Institute
for Health and Welfare, Kuopio); Marjut Roponen, PhD, (National
Institute for Health and Welfare, Kuopio).
France: Amandine Chauveau, PhD, (University Hospital of Besan-
çon, Besançon); Marie‐Laure Dalphin, PhD, (University Hospital of
Besançon, Besançon); Vincent Kaulek, PhD, (University Hospital of
Besançon, Besançon).
Germany: Martin Depner, PhD, (Dr von Hauner Children's Hospi-
tal, Ludwig Maximilian University, Munich); Markus Ege, MD, (Com-
prehensive Pneumology Center Munich, Member of the German
Center for Lung Research, Munich); Jon Genuneit, MD, (Ulm Univer-
sity, Ulm); Georg Loss, PhD, (Dr von Hauner Children's Hospital, Lud-
wig Maximilian University, Munich); Petra Pfefferle; PhD, (Institute
for Laboratory Medicine and Pathobiochemistry, Molecular Diagnos-
tics, Philipps University of Marburg, Marburg); Harald Renz, PhD,
(Institute for Laboratory Medicine and Pathobiochemistry, Molecular
Diagnostics, Philipps University of Marburg, Marburg); Bianca
Schaub, MD, (Comprehensive Pneumology Center Munich, Member
of the German Center for Lung Research, Munich).
Switzerland: Charlotte Braun‐Fahrländer, MD, (Swiss Tropical and
Public Health Institute, University of Basel, Basel); Remo Frei, PhD,
(Christine Kühne‐Center for Allergy Research and Education (CK‐
CARE), Davos; Swiss Institute of Allergy and Asthma Research (SIAF),
University of Zurich, Davos); Caroline Roduit, MD (Children's Hospi-
tal, University of Zürich, Zürich).
The Netherlands: Gert Doekes, (Utrecht University, Institut for
Risk Assessment Sciences (IRAS), Utrecht).
DOI: 10.1111/all.13571
Do mucosal biomarkers reveal the immunological state
associated with food allergy?
To the Editor,
As food allergy is an immunological disorder that affects mucosal
surfaces, the search for biomarkers may be promising for reflecting
an implication of the mucosal immune system. The purpose of this
letter was to report the ability of the mucosal biomarkers to identify
food allergy patients. A systematic review (SR) was undertaken to
evaluate the mucosal biomarkers associated with food allergy. Search
strategies in the LILACS, LIVIVO, PubMed, Science Direct, Scopus,
and Web of Science databases included the following terms: (allergy
OR allergies OR allergic OR allergen OR allergenic OR “food allergy”
OR “food allergies”) AND (food OR egg OR milk OR peanut OR dairy
OR nut) AND (salivary OR “saliva” OR “Saliva”[Mesh] OR nasal OR
lacrimal OR gut OR fecal OR “oral fluid”) AND (“Biomarkers”[Mesh]
OR biomarker OR “biomarkers” OR “biological marker” OR “biological
markers” OR marker OR markers OR biomolecule OR biomolecules
OR IgA OR IgE OR “secretory antibodies”). The search databases and
methods are detailed in Figure S1.
Twenty‐two studies met the eligibility criteria and were included
in this SR. The sample size was composed of 1950 subjects (1220
food allergy cases and 730 controls). Sixteen different biomarkers
were assessed (Figure 1). Eosinophil cationic protein (ECP) was the
most commonly reported biomarker (nine studies), followed by fecal
calprotectin and IgA/SIgA (six studies) and by IgE and α1‐antitrypsin
(AAT) in four studies. Eosinophil protein X, tumor necrosis factor‐α
(TNFα), and tryptase were reported in three studies. Other biomark-
ers were reported twice or once such as eosinophil‐derived neuro-
toxin (EDN), histamine, human β‐defensin 2 (HBD2), metabolites,
B‐cell‐activating factor (BAFF), 5‐hydroxytryptamine, myeloperoxi-
dase (MPO), prostaglandin D2 (PGD2), and peroxidase. (Table S1).
Eighteen studies reported biomarkers that may be useful for diagno-
sis or treatment follow‐up. A higher concentration of gut/fecal or
salivary biomarkers in allergic patients or after challenge test than
healthy controls or negative challenge was reported. All studies
reported that the double‐blind, placebo‐controlled food challenge
(DBPCFC) was done for diagnosis purposes. However, only few
studies detailed if a challenge test was carried out before or after
the collection of sample.
Four studies did not show differences in biomarker levels
between patients and controls. Fecal and gut lavage fluid was the
most frequently studied samples, whereas only two studies analyzed
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